EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy

Annie Tang, Toshifumi Yokota iD

Genes · 2025

DOI: 10.3390/genes16070777 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Annie Tang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of Alberta, 116 St. & 85 Ave., Edmonton, AB T6G 2R3, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Exons, Genetic Therapy, Dystrophin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a severe inherited muscle-wasting disorder that is associated with severe morbidity and mortality globally. Current treatment options have improved the quality of life of patients, but these treatments are only palliative. There is a need for more DMD treatment options. Antisense oligonucleotide (ASO) therapies have emerged as a promising personalized treatment option for patient groups that possess specific mutations. A subset of these therapies can skip over frame-disrupting exons in the DMD gene and can partially restore dystrophin production for individuals with DMD. One novel exon skipping therapy currently being investigated is brogidirsen, an exon 44 that targets ASO using a novel dual-targeting approach. This article will provide an overview of brogidirsen’s history and current clinical trial developments. It will summarize how this investigational therapy compares with other pre-clinical and clinical trial-stage ASO therapies targeting exon 44. Current advances and challenges faced by RNA-based therapies will also be discussed. Overall, brogidirsen is a promising potential addition to existing DMD treatment options, with its clinical trial results showing expression levels above that of the maximum amount of dystrophin expression achieved by current FDA- and EMA-approved exon-skipping DMD therapies. Further research will be needed to determine its overall efficacy and ability to overcome the known limitations faced by other existing ASO therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneExonsGenetic TherapyDystrophinOligonucleotides, AntisenseOligonucleotidesHumansAnimalsMorpholinos

Stichwörter der Autor:innen

NS-089/NCNP-02antisense oligonucleotideantisense therapeuticsbrogidirsenclinical trialduchenne muscular dystrophydystrophinexon 44exon skippingsplice modulation

Substanzen

DystrophinOligonucleotides, AntisenseOligonucleotidesDMD protein, humangolodirsenMorpholinos

Autor:innen und Institutionen

  • Department of Medical Genetics, University of Alberta, 116 St. & 85 Ave., Edmonton, AB T6G 2R3, Canada.

ORCID-Profile: Toshifumi Yokota

Zitieren

APA

Tang, A., & Yokota, T. (2025). Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy. Genes. https://doi.org/10.3390/genes16070777

Vancouver

Tang A, Yokota T. Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy. Genes. 2025. doi:10.3390/genes16070777

BibTeX
@article{Tang2025,
  author = {Tang, Annie and Yokota, Toshifumi},
  title = {Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16070777}
}
Kostenlos starten →